RU2257213C2 - Agent for treating and preventing iron-deficiency conditions in animals - Google Patents

Abstract

FIELD: veterinary.

SUBSTANCE: agent is based on complex compound of colloidal iron liganded by polyoxymethylene-lauric alcohol and contains following components, mg: colloidal iron 50.0-60.0, lauric alcohol 0.1-0.3, copper 0.1-0.3, zinc 0.1-0.3, cobalt 0.1-0.3, selenium 0.001-0.005, and water to 1000. Agent can further contain 30.0-50.0 mg glucose and 0.1-0.6 mg polyvinyl alcohol.

EFFECT: enabled therapeutical and preventive efficiency at low toxicity, the same dispersity, and high stability upon storage.

3 tbl, 7 ex

Description

The invention relates to the field of veterinary medicine and relates to means for treating and preventing animal diseases caused by a lack of iron in their body, mainly alimentary anemia, secondary anemia, as well as to increase the safety and productivity of farm and carnivorous animals.

Alimentary anemia (physiological anemia, iron deficiency anemia) is a disease characterized by a disorder of the blood-forming organs in young animals. This disease is found everywhere, mainly in the autumn-winter and early spring periods, mainly in piglets aged 5 to 35 days and less often in young animals of other animal species. In diseased animals, a decrease in the formation of red blood cells, a low hemoglobin content, a decrease in resistance to other diseases are noted, which causes significant economic damage to pig farming. In most households, the mortality rate reaches 10-15% (1).

The main cause of nutritional anemia in modern conditions is iron deficiency, which occurs due to a mismatch between the growth rate of newborns and the intake of trace elements with mother's milk. In addition, a deficiency of vitamins B ₁₂ , C, folic acid, protein, as well as trace elements of cobalt, copper, iodine, selenium, manganese, etc., contributes to the violation of iron absorption.

Against the background of anemia, piglets develop age-related immunodeficiency, leading to inhibition of erythropoiesis, the occurrence of secondary diseases of the digestive and respiratory systems.

In a patient with young anemia, oxidative processes are disturbed and oxygen starvation of tissues develops, which leads to the development of degenerative changes in internal organs. Therefore, it is proposed to consider anemia as a general pathological process, accompanied by a violation of the activity of many organs and systems of the animal organism (2).

For the treatment and prevention of nutritional anemia, iron-containing drugs are used both for intramuscular administration and for oral administration.

Almost all known iron preparations for oral administration are poorly tolerated, causing dyspepsia. In this case, the severity of diarrhea is stronger, the more will remain in the intestines of non-absorbed iron. In this regard, it is impossible to conduct a course of treatment to the end and achieve the desired results.

Injection preparations are mainly complex compounds of iron with ligands of various origins: polyhydric alcohols (sorbitol), dextran, dextrin, etc., which are administered to animals separately or with the addition of various sets of trace elements salts.

The known drug “Ferroglukin” for the treatment and prevention of nutritional anemia containing a complex compound of iron with low molecular weight dextran and water in an effective ratio (3).

The known drug “Ferbitol” for the treatment and prevention of iron deficiency conditions, containing a complex compound of an iron salt with sorbitol, citric acid, dextrin as a stabilizer and water in an effective ratio (4).

A known drug for the treatment and prevention of anemia containing a complex compound of ferric chloride hydrate with hydrazine hydrate and water in an effective ratio (5).

A known drug for the treatment and prevention of anemia containing a complex compound of iron with starch and water in an effective ratio (6).

Known drug for the treatment and prevention of nutritional anemia containing a complex compound of iron with a polymer ligand and water. As the polymer ligand, we use compounds obtained by the interaction of hydroxycarboxylic acid, polyhydric alcohol and an epoxy compound, or products obtained by the interaction of sucrose, polyhydric alcohol and an epoxy compound in an effective ratio (7).

The known drug "Microaneminum" for the treatment and prevention of nutritional anemia, containing a complex compound of iron with low molecular weight dextran, copper, cobalt and water in an effective ratio (8).

Known drug “Biofer” for the prevention of nutritional anemia, containing a liquid extract of aloe and an aqueous solution of ferroglukin in an effective ratio (9).

The well-known drug “Ferox” for the prevention of nutritional anemia is a Hanks solution enriched in cationic iron in a concentration of 1.0 ± 0.15% (10).

A known drug for the prevention of nutritional anemia of piglets containing a complex compound of iron with low molecular weight dextran, copper, cobalt, selenium and water (11).

A known drug for the treatment and prevention of anemia containing a complex compound of iron with a physiologically active polymer and water (12).

A known drug for the treatment and prevention of iron deficiency anemia of various etiologies containing a complex compound of iron with sorbitol, sucrose and water (13).

A known drug for the treatment and prevention of iron deficiency anemia in farm animals, containing complex compounds of zinc and iron with raw cane sugar and water (14).

A known drug for the treatment and prevention of iron deficiency anemia in farm animals, containing complex compounds of zinc and iron with beet sugar and water (15).

The known drug Suiferrovit for the treatment and prevention of nutritional anemia containing inactivated normal serum of pigs, a complex compound of iron with low molecular weight dextran, cobalt, copper, calcium, vitamins B ₁ , B ₂ , B ₆ , PP and water (16).

The drug “Ursoferran-100” is known for the treatment and prevention of nutritional anemia, which contains iron (III) -dextran heptonic acid and phenol as a preservative as the active substance (17).

Also known is the drug “Brij-35” (polyoxyethylene lauric alcohol) of the general formula C ₁₂ H ₂₅ (OCH ₂ CH ₂ ) _2n · OH, n = 23, used in clinical and scientific laboratories for quick cleaning and washing of autoanalyzers (18, 19).

The closest to the invention according to the set of essential features is the preparation "Bioferrinitis" for the treatment and prevention of iron deficiency conditions in animals, containing a complex compound of colloidal iron with gluconic acid as a ligand, trace elements and water, while in 1000 mg of solution contains: Fe (III) 50 mg, Cu (II) 0.16 mg, Zn (II) 0.1 mg, Co (II) 0.12 mg, Se 0.00015 mg, NaCl 0.9 mg and water - the rest (20).

The disadvantages of the known drugs, including the prototype drug, are their limited therapeutic and prophylactic efficacy and toxicity due to the significant presence of unbound iron in their composition, dimensional heterogeneity of particles of iron-containing complexes and a change in their dispersion (formation of agglomerates) and storage stability, which leads to incomplete absorption of iron as a result of a deficiency or violation of the production of biologically active substances-hemostimulants in the body animals.

The objective of the present invention was to develop a drug for the treatment and prevention of iron deficiency conditions in animals, combining high therapeutic and prophylactic efficacy, good tolerance, low toxicity, preservation of dispersion and high storage stability.

The technical result from the use of the present invention is to expand the arsenal of drugs for the treatment and prevention of iron deficiency conditions in animals with high therapeutic and prophylactic effectiveness by reducing toxicity, good tolerance, maintaining dispersion and high stability of the iron-containing complex during storage.

The specified technical result was achieved by creating a drug for the treatment and prevention of iron deficiency conditions in animals, characterized by the following set of features.

The proposed drug contains a complex compound of colloidal iron with a ligand, a set of trace elements and water, moreover, it contains polyoxyethylene lauric alcohol as a ligand, and copper, zinc, cobalt and selenium as trace elements in the following ratio of ingredients, mg:

Colloidal iron 50.0-60.0

Polyoxyethylene lauric alcohol 0.1-0.3

Copper 0.1-0.3

Zinc 0.1-0.3

Cobalt 0.1-0.3

Selenium 0.001-0.005

Water up to 1000.0

If necessary, to improve the absorption of iron in the animal’s body, the proposed preparation may additionally contain glucose, preferably in an amount of 30.0-50.0 mg.

If necessary, to create the body of the animal depot of the proposed drug, it may additionally contain polyvinyl alcohol, preferably in an amount of 0.2-0.6 mg.

The present invention includes the following set of essential features that provide a technical result in all cases for which legal protection is sought:

1. The drug for the treatment and prevention of iron deficiency in animals.

2. Colloidal iron in an amount of 50.0-60.0 mg.

3. Polyoxyethylene lauric alcohol as a ligand in an amount of 0.1-0.3 mg.

4. Copper in an amount of 0.1-0.3 mg.

5. Zinc in an amount of 0.1-0.3 mg.

6. Cobalt in an amount of 0.1-0.3 mg.

7. Selenium in an amount of 0.001-0.005 mg.

8. Water in an amount up to 1000.0 mg.

The signs of the invention, characterizing the proposed drug and coinciding with the signs of the prototype, including the generic concept, reflecting the purpose, are:

1. The drug for the treatment and prevention of iron deficiency in animals.

2. A complex compound of colloidal iron with a ligand.

3. Copper.

4. Zinc.

5. Cobalt.

6. Selenium.

7. Water.

Compared with the prototype drug, an essential distinguishing feature of the proposed drug is that it contains polyoxyethylene lauric alcohol as a ligand.

The present invention also contains other distinctive features expressing specific forms of execution or special conditions for its use:

1. The preparation further comprises glucose, preferably in an amount of 30.0-50.0 mg.

2. The preparation additionally contains polyvinyl alcohol, preferably in an amount of 0.2-0.6 mg

The proposed drug expands the arsenal of drugs for the treatment and prevention of iron deficiency in animals, has high therapeutic and prophylactic efficacy by reducing toxicity, good tolerance, maintaining dispersion and stability of the iron-containing complex during storage.

The achievement of the technical result from the use of the proposed preparation is explained by the fact that as a result of the interaction of colloidal iron particles with polyoxyethylene lauric alcohol, strong physical and chemical bonds arise between them, which lead to the formation of a surface on the colloidal iron particles with hydrophilic properties, which gives the particles of the complex pharmacological properties. The degree of hydrophilization of colloidal iron particles was evaluated by the heat of interaction of the starting ingredients.

Treatment of colloidal iron with polyoxyethylene lauric alcohol in the claimed concentration range allows to obtain an iron-containing complex of uniform size and maintain it in a dispersed and stable state for a long time. The resulting compound withstands boiling, as well as repeated freezing to -20 ° C followed by thawing.

In addition, the presence in the proposed preparation of glucose in the claimed concentration improves the absorption of iron in the animal.

The presence in the proposed preparation of polyvinyl alcohol in the claimed concentration allows you to create in the body of the animal depot of the drug after its introduction. Adsorbed on the particles of the iron-containing complex, polyvinyl alcohol molecules form solvate shells around the particles of the complex and turn the complex suspension into a kinematically stable form, which leads to the formation of a drug depot when it is introduced into the animal body. The drug is deposited in the liver and blood organs. The deposition of the drug provides a better distribution of the active substance in the animal’s body, prolonging its action, does not cause an adverse reaction of its tissues and reduces the treatment time for sick animals. The drug enhances redox reactions and blood formation processes, enhances the synthesis of hemoglobin, myoglobin, increases the permeability of cell membranes, activates water-salt metabolism, as well as the action of trace elements (selenium, iron, cobalt, copper and zinc) enzymes.

An analysis of the state of the art by the applicant, including a search by patent and scientific and technical sources of information, and identification of sources containing information about analogues of the proposed drug, made it possible to establish that the applicant did not find a source characterized by features that were identical (identical) to all essential features of the proposed drug. The definition from the list of identified analogues of the prototype as the closest in the totality of the features of the analogue allowed us to establish a set of essential distinguishing features in relation to the applicant’s perceived technical result in the proposed preparation set forth in the claims.

Therefore, the proposed drug meets the condition of patentability "novelty."

To verify the compliance of the proposed drug with the patentability condition “inventive step”, the applicant conducted an additional search for known solutions to identify features included in the distinctive part of the independent claim.

Drugs for the treatment and prevention of iron deficiency in animals are known. Information about them is given in the section "prior art" description of the present invention. An essential distinguishing feature of the proposed drug is introduced in its composition polyoxyethylene lauric alcohol in an amount of 0.1-0.3 mg. The indicated symptom is functionally independent.

It is known to use polyoxyethylene lauric alcohol for quick cleaning and washing of autoanalyzers in clinical and scientific laboratories (18, 19).

The inventors have discovered a new property of polyoxyethylene lauric alcohol in the claimed concentration range - to stabilize colloidal iron, giving it pharmacological properties and an agretatively stable form of a suspension of an iron-containing complex during long-term storage.

The search results showed that the proposed solution does not follow explicitly for the specialist from the prior art set forth in the corresponding section of the description (no solutions having features matching the totality of distinctive features of the present invention have been identified), and the effect of the essential features of the proposed inventions of transformations to achieve a technical result.

Therefore, the proposed drug meets the condition of patentability “inventive step”.

The effectiveness of the proposed drug is illustrated by examples of its use, which does not limit the scope of the invention.

Example 1

Ferric chloride (FeCl ₃ · 6H ₂ O) in the amount of 15.5-16.0 kg is dissolved in 30 l of distilled water. The resulting solution was filtered and transferred to the reactor. With continuous operation of the stirrer, a saturated stream of saturated ammonium carbonate solution [NH ₄ (CO ₃ ) ₂ ] is fed into the reactor at an average speed of 100 cm ³ / min in a volume of 22-25 L to establish a pH of the reaction mixture in the range of 6.8-7, 2. In the process of introducing into the reactor a saturated solution of ammonium carbonate in the range of pH 3.3-3.8, a gel of colloidal iron is formed, which is broken by vigorous stirring and the addition of a saturated solution of ammonium carbonate.

The resulting colloidal iron solution is ultrafiltered with dialysis by tap water to release the colloidal iron solution from ammonium chloride (NH ₄ Cl ₂ ) and carbon dioxide (CO ₂ ) resulting from the reaction of ferric chloride with ammonium carbonate. The end of dialysis is determined by the absence of chlorine ions in the water leaving the ultrafiltration apparatus in reaction with silver nitrate (AgNO ₃ ). At the end of dialysis, the pH of the colloidal iron solution is adjusted to 9.0–9.2 by the addition of 10% sodium hydroxide (NaOH) solution and, with constant stirring, the reaction mixture is left for 8-10 hours. After this, the reaction mixture is neutralized by the addition of citric acid to a pH of 6.5-6.8 and heated to 80-85 ° C without turning off the stirrer. At this time, the color of the reaction mixture changes from red-brown to dark red (black) opalescent with the formation of a black cone in the solution, which indicates the receipt of colloidal iron. To obtain an iron-containing complex, a mixture of polyoxyethylene lauric alcohol, glucose and polyvinyl alcohol is added to a hot solution of colloidal iron so that the final concentration of polyoxyethylene lauric alcohol, glucose and polyvinyl alcohol in 1000 mg of the preparation is 0.1-0.3; 30.0-50.0 and 0.2-0.6 mg, respectively. As a result of the interaction of colloidal iron particles with polyoxyethylene lauric alcohol in the claimed concentration, strong physicochemical bonds arise between them, which preserve the dispersion and stability of the iron-containing complex during storage and the formation of a hydrophilic surface on the colloidal iron particles, which gives the particles of the obtained complex pharmacological properties .

Glucose in the claimed concentration range is used in the preparation to improve iron absorption in the animal.

Polyvinyl alcohol in the claimed concentration range is used to create the proposed preparation in the animal depot body after its administration.

The colloidal iron content in 1000 mg of the drug should be 50.0-60.0 mg. If the concentration of colloidal iron is different from the above, the solution is concentrated or diluted in an ultrafiltration unit.

After that, the solution is cooled to 60 ° C, filtered through an ion exchange resin, the volume of the complex obtained is measured, and a set of trace elements in the form of their salts are added to it: CuSO ₄ · 5H ₂ O, ZnCl ₂ , CoCl ₂ · 6H ₂ O and Na ₂ SeO ₃ - in such a way that the content of Cu ⁺⁺ , Zn ⁺⁺ and Co ⁺⁺ ions in 1000 ml of the preparation is 0.1-0.3 mg, and Se in the range of 0.001-0.005 mg. In this case, each salt is dissolved separately in 0.5 l of distilled water, the solution is brought to a boil, and the boiling solution is introduced in a thin stream into the solution of the iron-containing complex with vigorous stirring. The optimal formulation of the proposed drug are shown in table 1.

The resulting preparation is subjected to chemical and biological control.

Iron in the composition of the drug is determined by complex metric titration with sulfosalicylic acid. Copper, zinc, cobalt and selenium are determined using a Saturn atomic absorption spectrophotometer according to GOST 15150-69. The drug is obtained in the form of an aqueous solution, which is a dark brown liquid with a pH of 6.5-6.8. The drug should be stored in glass or plastic bottles. Storage in containers made of ferrous metals or aluminum is unacceptable due to its corrosive activity.

Acute toxicity and the maximum tolerated dose of the drug for laboratory animals was determined according to the “Methodological guidelines for determining the toxic properties of drugs used in veterinary medicine and animal husbandry”, approved by the USSR Ministry of Health, VASKHNIL and GUV Gosagroprom of the USSR. LD ₅₀ for white mice weighing 18.0 to 20.0 g was 1.02 cm ³ / goal. According to the accepted classification, the drug is low toxic.

The proposed drug is used for the treatment and prevention of animal diseases caused by a lack of iron in their body, mainly nutritional anemia, secondary anemia, increase the safety and productivity of agricultural and carnivorous animals.

Before use, the vial with the drug is thoroughly shaken. The drug is administered to animals intramuscularly in the neck or thigh once a day.

For prophylactic purposes, the drug is administered to animals in the following doses:

- sheep, goats 15 days before lambing, 5000.0 mg;

- sows 15 days before farrowing 10,000.0 mg;

- for cows 15 days before calving, 1000.0-2000.0 mg per 40 kg of live weight;

- piglets at 2-4 days of life 2000.0 mg;

- calves on the 3-4 day of life 3000.0 mg;

- dogs 500.0 mg per 10 kg of live weight;

- mink during the rut period at 300.0 mg.

For therapeutic purposes, the drug is administered twice with an interval of 7-14 days in the following doses:

- piglets 200.0 mg / kg body weight;

- calves, lambs 100.0 mg / kg body weight;

- dogs 1000.0 mg per 10 kg of live weight;

- cats 200.0 mg / kg body weight;

- mink 500.0 mg per head.

Example 2

Studies of the proposed drug, manufactured as described in example 1, for toxicity in laboratory animals.

In total, 60 white mice and 1 rabbit were used in the experiment with a live average weight of 16-18 g and 2.5 kg, respectively.

Doses of the drug from 250.0 to 1700.0-2000.0 mg / goal were tested. three methods of administration: cutaneous application to the rabbit, subcutaneous and oral administration to white mice.

As a result of the studies established:

1. Double skin rubbing of the drug to the rabbit does not have a dermonecrotic effect.

2. Bioassay on white mice with oral 3-time administration of the drug in doses of 250.0 and 500.0 mg / goal. its toxic effect has not been established.

3. In an acute experiment, when high doses of the drug were administered to mice in the stomach, the Kerber method determined the average lethal dose of LD ₅₀ , which caused a toxic effect with a fatal outcome of 50% of the animals within 24 hours. The research results are shown in table 2. LD _{50 of the} drug is 1020.0 mg / goal.

In accordance with the established indicator on the toxicity scale, the drug belongs to low-toxic substances.

The use of the drug in doses of 700.0-1700.0 mg / goal. manifested by a change in the general condition of white mice, i.e. with increasing doses, the toxic effect of the drug increases.

The clinical manifestation of the toxic effect of increased doses of the drug occurs 7-10 minutes after administration. In this case, there was a sharp depression, frequent breathing, trembling or strong muscle twitching, increased sensitivity to external stimuli, bouncing like in a “hot pan”, peeping. Some animals died from doses of 1000.0-1200.0 mg / goal. 40-50 minutes after administration, from doses of 1400.0-1700.0 mg / goal. - within 30 minutes

4. Subcutaneous administration of the drug in doses of 250.0 and 500.0 mg / goal. did not cause toxic effects and death of mice. The introduction of the drug at a dose of 700.0 mg / goal. caused a slight degree of oppression, disappearing after 30 minutes. From doses of 1000.0; 1500.0 and 2000.0 mg / goal. observed the death of mice.

5. Repeated (within 25 days) oral administration of the drug to mice at a dose of 250.0 mg / goal. had no harmful toxic effect on mice, which indicates the absence of cumulative properties of the drug.

As a result of studies on laboratory animals, it was found that the proposed drug belongs to low-toxic compounds and does not have dermonecrotic and cumulative effects.

Example 3

A test of the effectiveness of the proposed drug, manufactured as described in example 1, and containing, mg:

Colloidal Iron 50.0

Polyoxyethylene lauric alcohol 0.1

Glucose 30.0

Polyvinyl alcohol 0.2

Copper 0.1

Zinc 0.1

Cobalt 0.1

Selenium 0.001

Water up to 1000.0

in the conditions of one of the farms of the Ivanovo region in the treatment of small pets with alimentary hypochromic anemia.

The proposed drug was prescribed to small pets with blood loss in the postoperative period of 1000.0 mg per kg of body weight three times a month with an interval of 10 days. In the experiment, 5 dogs of the Central European Shepherd breed and 3 cats were used. With the introduction of this drug, the postoperative period was easy, rapid tissue regeneration and suture healing, restoration of appetite, animal mobility, allergic and intoxication effects on drug administration were not established.

As a result of using the drug, local or general complications were not observed.

Thus, the proposed drug is suitable for the treatment of animals with anemia caused by blood loss and circulatory disorders.

Example 4

Comparative tests of the effectiveness of the proposed drug, manufactured as described in example 1, and containing, mg:

Colloidal iron 55.0

Polyoxyethylene lauric alcohol 0.2

Glucose 40.0

Polyvinyl alcohol 0.4

Copper 0.2

Zinc 0.2

Cobalt 0.2

Selenium 0.003

Water up to 1000.0

and the drug “Ferroglukin-75” in the conditions of one of the farms of the Ivanovo region on the livestock of three-day-old sucking piglets with alimentary hypochromic anemia. In the experiment used 25 goals. The observation period is 20 days. The animals were divided into three groups: 1 group of 10 animals for testing the proposed drug, 2 group of 10 animals for testing “Ferroglukin-75” and 3 group of 5 animals served as a control and were not subjected to treatment with an iron-containing preparation. The pigs of groups 1 and 2 were injected with test iron preparations of 1500.0 mg intramuscularly in the neck. After 10 days, repeated administration was carried out in the same doses.

As a result of the studies, it was found that the proposed drug allows maintaining the safety of suckling piglets by 100%, while the growth rate of piglets increases, the daily biomass increase was 4.8–9.6% more than in animals of the control group. When using “Ferroglukin-75” the results were similar. In the control group not treated with iron-containing preparations, the livestock safety was 60%, and the surviving pigs were lagged behind in growth and development.

Example 5

Comparative tests of the effectiveness of the proposed drug, manufactured as described in example 1, and containing, mg:

Colloidal iron 55.0

Polyoxyethylene lauric alcohol 0.2

Glucose 40.0

Polyvinyl alcohol 0.4

Copper 0.2

Zinc 0.2

Cobalt 0.2

Selenium 0.003

Water up to 1000.0

and the drug “Ursoferran-100” (Germany) in the conditions of one of the farms of the Ivanovo region on the number of suckling piglets of 3-4 days of age. The preparations were administered intramuscularly to animals in the neck at a dose of 1500.0-2000.0 mg. Previously proposed drug was processed 1 group of animals in the amount of 6 heads of suckling pigs. Piglets were observed for 10 days. During the observation period, side effects and complications were not observed.

After that, the proposed drug was processed 2 group of animals in the amount of 65 goals. Observation of the animals was carried out for 51 days. No complications were observed during the observation period.

The proposed drug was processed 3 group of animals in the amount of 50 goals. The animals were observed for 51 days. No complications were observed during the observation period. At weaning, the average weight of one pig was 12 kg.

In parallel with testing the proposed drug on the farm used the drug "Ursoferran-100" (Germany) on 853 heads of sucking piglets 3-4 days of age. At weaning, the average weight of piglets was also 12 kg.

According to its effect on piglets, the proposed drug is not inferior to the drug "Ursoferran-100" (Germany).

Example 6

The tests of the effectiveness of the proposed drug, manufactured as described in example 1, and containing, mg:

Colloidal Iron 50.0

Polyoxyethylene lauric alcohol 0.1

Glucose 30.0

Polyvinyl alcohol 0.2

Copper 0.1

Zinc 0.1

Cobalt 0.1

Selenium 0.001

Water up to 1000.0

in the Perm region in the practice of treating iron deficiency conditions in minks.

The treatment was carried out on a group of minks from 20 individuals of 12 months of age with obvious signs of necrotic dermatitis (scratching, skin necrosis, damage to the coat). The drug was administered intramuscularly at a dose of 1000.0 mg per kg of animal weight three times with an interval of 10 days. At the same time, general strengthening and anti-inflammatory therapy was performed.

During the treatment period, the clinical condition of the animals gradually normalized by the 30-day period, and at the end of the treatment period the animals were motile, ate well-fed food and had no skin defects. The safety of animals in the group was 98% with a good boot assessment. Their hairline was characterized as thick, smooth and silky. Allergic and intoxication effects on drug administration have not been established.

Example 7

Comparative tests of the effectiveness of the proposed drug manufactured as described in example 1, containing, mg:

Colloidal Iron 50.0

Polyoxyethylene lauric alcohol 0.1

Glucose 30.0

Polyvinyl alcohol 0.2

Copper 0.1

Zinc 0.1

Cobalt 0.1

Selenium 0.001

Water up to 1000.0

and the preparation “Bioferrinite” (prototype) in the conditions of one of the farms of Suzdal district of Vladimir region on three-day-old piglets-suckers.

For the treatment of piglets, the proposed preparation with a 2-year shelf life was used, and “Bioferrinite” after a year of storage. The proposed drug was administered to sucking pigs at doses of 1000.0; 2000.0 and 5000.0 mg. The drug "Bioferrinitis" was used according to the manual.

The dynamics of the increase in mass of animals is shown in table 3. Blood was taken from the tail vein immediately before the introduction of drugs and later after weighing the animals.

As a result of tests, it was found that both drugs were harmless. The physiological condition of the animals was rated as good. At the injection site, no adverse drug effects were detected. In some cases, the weight gain of the piglets in the group treated with the proposed drug exceeded the weight of the animals treated with Bioferrinitis, while there were no differences in the content of clinical blood parameters in both groups of animals.

After the safety of the preparations was established, 142 piglets-suckers were additionally treated with the proposed preparation in doses of 1000.0 and 2000.0 mg, depending on the physiological state of the animals. All piglets remained alive, their physiological condition was assessed as good.

In similar conditions, Bioferrinitis treated 89 suckling pigs. In this group, 2 pigs died, and 18 animals had swelling at the injection site, which sometimes turned into ulcers. The negative effects of the introduction of the drug “Bioferrinitis” disappeared after 12-20 days.

Thus, the proposed drug has a more pronounced therapeutic efficacy and long shelf life (2 years - observation period) compared with the prototype drug.

Thus, the above information indicates the fulfillment when using the invention of the following set of conditions:

- a drug embodying the invention is intended for use in veterinary medicine;

- for the proposed invention in the form as described in the independent claim, the possibility of its implementation using the means and methods described in the application or known prior to the priority date is confirmed;

- when using the proposed drug, a technical result is achieved, provided for by the task of creating the invention.

Therefore, the present invention meets the condition of patentability “industrial applicability”.

Sources of information

1. Jonauskas L.D. Prevention of nutritional anemia of sucking piglets with iron supplements added to feed. Abstract of diss. Cand. veterinary sciences. - M., 1980

2. Karput I.M. Hematological atlas of farm animals. - Minsk, Urajay, 1986

3. The regulations for the production of ferroglukin (with an iron content of 75 mg / ml). Minsk Plant of Medications, 1968 - 20 p.

4. Auth. testimonial. USSR No. 306847, A 61 K 25/02, 06/21/71

5. Auth. testimonial. USSR No. 355955, A 61 K 25/02, 10.23.72 g

6. Auth. testimonial. USSR No. 683745, A 61 K 33/26, 09/05/79

7. Auth. testimonial. USSR No. 730276, A 61 K 33/26, 39/00; 04/25/80

8. Auth. testimonial. USSR No. 1328956, A 61 K 33/26, 1984

9. Manual on the use of “Biofer” in veterinary medicine. Approved by the GUV of the Ministry of Agriculture and the Republic of Belarus 02.17.95

10. Application No. 92006855/15 for the grant of a patent of the Russian Federation invention, A 61 K 33/26, 02.27.95,

11. Auth. testimonial. USSR No. 1797196, A 61 K 33/04, 02/10/96.

12. RF patent No. 2079305, A 61 K 33/26, 05.20.97.

13. RF patent No. 2098101, A 61 K 33/26, 12/10/97.

14. RF patent No. 2188022, A 61 K 33/26, 08.27.02

15. RF patent No. 2188650, A 61 K 33/26, 09/10/02

16. Index of drugs by their pharmacological action and use. Warsaw Center for Scientific Information "Polfa", 1987. - P.139.

17. General and clinical veterinary formulation: Reference book / Ed. prof. V.N. Zhulenko. - M .: Kolos, 1998 .-- P.203.

18. BME, M., publishing house “Sov. Encyclopedia ”, 1977, v. 7, 176-177.

19. Sigma-Aldrich Corporation Directory “Laboratory Reagents and Equipment Directory” for Russia, 2000-2001, p.241, catalog number 85. 636-6.

20. Veterinary drugs in Russia: Reference book / I.F. Klenova, N.A. Yaremenko. - M .: Selkhozizdat, 2000. - 296-297 (prototype).

Table 1
The optimal composition of the proposed drug for the treatment and prevention of iron deficiency in animals Name of ingredients Recipe mg Minimum Average Maximum Colloidal iron 50,0 55.0 60.0 Polyoxyethylene lauric alcohol 0.1 0.2 0.3 Glucose 30,0 40,0 50,0 Polyvinyl alcohol 0.2 0.4 0.6 Copper 0.1 0.2 0.3 Zinc 0.1 0.2 0.3 Cobalt 0.1 0.2 0.3 Selenium 0.001 0.003 0.005 Water up to 1000.0 up to 1000.0 up to 1000.0

table 2
Determination of LD _{50 of the} proposed drug for white mice Test doses, mg / goal. 0.25 0.5 0.7 1,0 1,2 1.4 1.7 Survived a goal. 8 8 6 4 3 1 0 It’s a goal. 0 0 2 4 5 7 8 Z (number of fallen) 2 1,0 3.0 4,5 6.0 7.5 - d (interval between doses) 0.25 0.2 0.3 0.2 0.2 0.3 - Zd - 0.2 0.9 0.9 1,2 2.25 -

n = 8, ∑ Zd = 5.45

LD ₅₀ = LD ₁₀₀ -5.45 = 1.02 ml / goal.

Table 3
Weight gain dynamics of suckling piglets after iron supplementation The name of the drug Dose of administration, mg Duration of observation and weight of piglets, kg 1 day 3 day 11 day 21 day



Suggested drug 1000,0 1,1
1,1
1,1 2.5
2,4
1,6 4.4
3.8
4.4 6.5
7.5
6.9 Average 1,08 2.17 4.20 6.97 2000.0 1,5
1,0
1,5 1.8
2.5
1,6 4.9
4.8
4.7 5,0
5.3
7.5 Average 1.25 1.97 4.80 5.93 5000.0 1,6
1,5
1,0 2,3
1,6
2.0 4,5
4.9
4.8 5.5
7.1
7.3 Average 1.36 1.97 4.73 6.63 “Bioferrinitis” 2000.0 1.4
1,0
1,1 2,3
1,6
2.0 4.6
3,5
4.2 7.0
6.0
7.0 Average 1.17 1.97 4.10 6.67

Claims (3)

1. The drug for the treatment and prevention of iron deficiency in animals, containing a complex compound of colloidal iron with a ligand, copper, zinc, cobalt, selenium and water, characterized in that it contains polyoxyethylene lauryl alcohol as a ligand in the following ratio of components, mg: Colloidal iron 50.0-60.0 Polyoxyethylene lauryl alcohol 0.1-0.3 Copper 0.1-0.3 Zinc 0.1-0.3 Cobalt 0.1-0.3 Selenium 0.001-0.005 Water Up to 1000.0 2. The drug according to claim 1, characterized in that it additionally contains glucose in an amount of 30.0-50.0 mg. 3. The drug according to claim 1 or 2, characterized in that it additionally contains polyvinyl alcohol in an amount of 0.2-0.6 mg.